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CASE REPORT
PULMONARY HEMORRHAGE AS A MANIFESTATION
OF SYSTEMIC LUPUS ERYTHEMATOSUS
Bruno Hollanda Santos, Rodrigo Ribeiro Santos, Celeide Fátima Santos, Adriana
Maria Kakehasi and Hermann Alexandre Vivacqua Von Tiesenhausen
SANTOS BH et al. - Pulmonary hemorrhage as a manifestation of systemic lupus erythematosus. Rev. Hosp. Clín. Fac. Med.
S. Paulo 59(1):47-50, 2004.
The authors report a case of a 19-year-old woman admitted for the investigation of fever and hemolytic anemia for the
previous 2 months. As an inpatient, she had convulsions and sudden loss of consciousness, developing hemoptysis, hypoxia,
and respiratory insufficiency. Examination showed pericardial effusions on the echocardiogram and bilateral alveolar
condensations on the thoracic radiograph. A hypothetical diagnosis of systemic lupus erythematosus was made, and
measurement of the antinuclear factor was requested along with daily pulse therapy methylprednisolone, in spite of which
the outcome was fatal. Afterwards, the result of the antinuclear factor test was positive, with a titer of 1:5120, showing a fine
punctiform pattern, fulfilling the criteria for systemic lupus erythematosus according to the American College of
Rheumatology. Secondary pulmonary hemorrhage in this connective tissue disease is an uncommon but serious complication
that involves a high level of mortality in spite of intensive treatment, as is also reported in the literature.
DESCRIPTORS: Alveolar hemorrhage. Systemic lupus erythematosus. Pulmonary capillaritis.
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A variety of noninfectious pulmo-
nary manifestations are frequently as-
sociated with systemic lupus ery-
thematosus (SLE), including pleurisy
and pleural effusion, which occur in
up to 60% of these patients1 and nor-
mally result in low morbidity and mor-
tality. Other pulmonary alterations as-
sociated with SLE include acute
alveolitis, pneumonitis, pulmonary
hypertension, pulmonary embolism,
bronchiolitis, and diffuse alveolar
hemorrhage (DAH). The first report of
DAH associated with SLE was made
by Osler in 1904, who reported the case
of a young patient who presented with
a cutaneous rash, glomerulonephritis,
anemia, and pulmonary involvement
with hemoptysis and bilateral alveolar
infiltration2. This is a rare clinical pic-
ture, with 73 cases reported in the sci-
entific literature, that presents a poor
prognosis, with a mortality of up to
45% of cases, irrespective of the early
initiation of immunosuppressant
therapy. The authors describe a case of
DAH in a patient with a diagnosis of
SLE.
CASE REPORT
A black 19-year-old female patient
was admitted to investigate continu-
ous fever associated with anemia of 2
months duration. She reported muscle
pain and lethargy and presented with
intensely pale mucosa. As an inpatient,
she had generalized recurrent convul-
sions, continuous generalized head-
ache with progressive intensity, and
uncontrollable vomiting. After 24
hours, there was drowsiness, mental
confusion, torpor, and coma, and the
patient was transferred to intensive
care. Computerized tomography was
undertaken of the skull, which showed
diffuse cerebral edema, blurring of the
cerebral sulci, and partial collapse of
the ventricles (Fig. 1). A cardiogram
showed pericardial effusions. A
hemogram revealed normocytic and
normochromic anemia (Hb 7.8 mg/dL,
ht 23.2 mg%), a low platelet count
(130,000 c/mm³), and an elevated re-
ticulocyte count (105,000 c/mm³), and
the indirect Coombs test was positive.
Renal function and urine sedimenta-
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tion were normal. A blood sample was
taken to determine whether antinuclear
factor was present, and pulse therapy
with methylprednisolone (1 g/day for
3 days) was initiated, considering the
diagnosis to be SLE. On the second
day of treatment, there was dyspnea,
cough, and voluminous hemoptysis
with hemodynamic repercussions. A
radiograph of the thorax was under-
taken that showed bilateral alveolar
condensations (Fig. 2). The patient de-
veloped acute respiratory insufficiency
requiring endotracheal intubation
when a large quantity of blood was
found inundating the airways. In spite
of these therapeutic measures, the pa-
tient died the same day. Later, the re-
sult of the antinuclear factor test was
shown to be positive at a dilution of
1:5120, with a fine punctiform pattern,
fulfilling the criteria by the American
College of Rheumatology to be clas-
sified as SLE3.
DISCUSSION
Although DAH is rare, it is a rec-
ognized complication of pulmonary
involvement in SLE. In 1904, Osler
described the clinical findings of a fe-
male patient, aged 24, who presented
with a cutaneous rash, anemia, nephri-
tis, hemoptysis, and bilateral alveolar
consolidations2. This was the first de-
scription associating pulmonary he-
morrhage with SLE. Since then, 72
cases have been well documented in
the literature. The incidence of this
complication is low, affecting less than
2% of patients with SLE4. Pulmonary
hemorrhage is associated with a high
mortality that can vary between 45%
and 60%5. The involvement of other
organs and systems, particularly the
kidneys, adversely affects the progno-
sis6. Young female patients with an av-
erage age of 29 are most commonly af-
fected, at a ratio of 4:14.
In the majority of cases, the diag-
nosis of SLE is already established an
average of 36 months before the occur-
rence of pulmonary bleeding. How-
ever, in 20% of cases where this is the
first manifestation of the disease, diag-
nosis is more complicated6. Recurrence
of bleeding can occur in patients who
survive their first episode of DAH7.
Clinical presentation includes
dyspnea, hypoxemia, and severe mu-
cocutaneous paleness, with or without
signs of external bleeding. Sudden on-
set of rhonchi and crackles on auscul-
tation are frequent findings. Hemop-
tysis is a common manifestation but
can be absent even in cases of massive
hemorrhage8.
A radiograph of the thorax showed
bilateral alveolar infiltration of rapid
development, and tomography of the
thorax showed lesions with greater
definition that revealed the most ap-
Figure 1 - Computerized tomograph of the brain showing diffuse cerebral edema, partial
collapse of the ventricles, and blurring of the cerebral sulci.
Figure 2 - Thoracic radiograph showing diffuse alveolar condensations and increase of cardiac
area.
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propriate location for pulmonary bi-
opsy9. Some studies show that mag-
netic resonance can be more sensitive
and specific for DAH than other diag-
nostic methods, making pulmonary bi-
opsy unnecessary to confirm the diag-
nosis.
The pulmonary biopsy showed ex-
tensive intra-alveolar hemorrhage,
which is the most common finding,
with red blood cells and cellular de-
bris filling the alveoli as a result of re-
cent bleeding4. In addition, the find-
ing of macrophages containing hemo-
siderin suggests previous bleeding.
The presence of necrotizing capilla-
ritis or necrotizing microangiitis ac-
cording to Liebow, is characterized by
foci of infiltration by pyknotic neutro-
phils in small arterioles, and necrotic
capillaries are marked in DAH induced
by SLE11. Although nonspecific, this
anatomical-pathological alteration as-
sociated with the clinical presentation
and the laboratory findings is of great
value establishing the etiology of
bleeding7,11.
The pathogenesis is not fully un-
derstood. The majority of studies re-
late DAH to the deposit of immuno-
complexes in the lungs7. Direct im-
munofluorescence shows deposits of
IgG and C3 in the basal membrane of
the pulmonary capillaries. However,
the absence of these findings in some
studies raises the possibility of other
mechanisms12.
Early treatment with corticos-
teroids is the most common form of
treatment. The variations in dosage,
duration of treatment, the route of ad-
ministration, and treatment monitoring
restrict conclusions about efficiency.
Cyclophosphamide has been used, in
some cases associated with steroids,
with contrasting results, and until now
with no proven scientific value4,5. Plas-
mapheresis has been used in a small
number of cases but has not been
shown to improve the prognosis of
these patients13. The prognosis is asso-
ciated with mortality in about 50% of
the cases.
CONCLUSION
Diffuse alveolar hemorrhage (DAH)
is a rare complication of SLE; it may
be the first manifestation of disease
and has a devastating evolution irre-
spective of the therapy initiated. Great
attention must be paid to possible di-
agnosis of DAH, since any delay in
therapy can directly influence the evo-
lution of the disease.
RESUMO
SANTOS BH e col. - Hemorragia
pulmonar como manifestação do
lúpus eritematoso sistêmico. Rev.
Hosp. Clín. Fac. Med. S. Paulo
59(1):47-50, 2004.
Os autores relatam o caso de uma
paciente de 19 anos admitida para in-
vestigação de febre e anemia hemo-
lítica, com dois meses de evolução.
Durante a internação apresentou crises
convulsivas tônico-clônicas e queda
súbita no nível de consciência, evolu-
indo com hemoptise, hipoxemia e in-
suficiência respiratória. Os exames evi-
denciaram derrame pericárdico ao
ecocardiograma e condensações al-
veolares bilaterais à radiografia de tó-
rax. Foi levantada a hipótese diag-
nóstica de lúpus eritematoso sistêmico
sendo solicitada a pesquisa do fator
antinuclear e iniciada terapia com pul-
sos diários de metilprednisolona, a
despeito da qual a paciente evoluiu
para o óbito. Posteriormente o resulta-
do do fator antinuclear mostrou-se po-
sitivo, em título de 1:5120, padrão
puntiforme fino, preenchendo critéri-
os para lúpus eritematoso sistêmico se-
gundo o Colégio Americano de Reu-
matologia. A hemorragia pulmonar se-
cundária a esta doença do tecido con-
juntivo é uma forma incomum e grave
de manifestação da doença que evolui
com alta mortalidade, apesar do trata-
mento intensivo, conforme descrito na
literatura.
DESCRITORES: Hemorragia
alveolar. Lúpus eritematoso sistê-
mico. Capilarite pulmonar.
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